Insights on GLP 1 Research


GLP-1 Research with Dr. Anne Nafziger

I’m Anne Nafziger. I’m medical director at the Albany. IMA Clinical Research site and I’m a principal investigator and sub-investigator at this site.

I think it’s it’s relatively easy to see how some of the recent progress in GLP-1 agonist research has impacted patients lives. And we know that because there are so many people seeking access to these medications because of the benefits that they get in terms of improving their diabetic control and assisting with weight loss.

And I think since we know that this class of drugs is so effective and safe, I think that that’s going to continue to spur research in terms of finding dose formulations that are easier to use or more acceptable, trying to develop oral agents, trying to develop things that can be taken less frequently, maybe things with fewer side effects.

And I think that that is really I think that’s really encouraging because we know that problems with obesity and obesity resulting in diabetes are not going to be easily solved through other interventions. By other interventions, I mean changing people’s diet, changing people’s activity levels, assisting them to lose weight without medications. So I think this is a really important and promising area for research, and I don’t think we’ll have any problems finding people that want to participate in that research to improve medications that we have available for people.

Patient Benefits: More Individualized Care

People who are in clinical studies get more attention. They get education that they wouldn’t in a usual health care setting. And and they get TLC from the site staff.

I think that individuals really appreciate the the personal interactions they can get when they’re in a clinical study.

Standard of Care: Delivering High Quality Patient Data

I’m committed to a high standard of patient care. And for me, that includes educating the participant about the study and the study interventions and addressing any concerns that they have, answering their questions, and then assuring that they’re kept as safe as possible while they’re in our studies. Another part of this commitment, I think, is ensuring that the research environment is safe, properly maintained and welcoming.

We really need to work as a team to make sure that the time and commitment that participants make to a study is going to result in high quality data.